sintilimab
eli lilly
['sintilimab', 'nsclc', 'lcsm,(-blcsm)', 'sclc']
for early stage, resectable nsclc - how many cycles of neo-adjuvant chemo-immunotherapy do we need? neoscore trial looked at mpr as primary endpoint, with carbo-nab pac, or pem + sintilimab mpr: 3 cyc slightly better than 2 sq higher mpr
#lcsm #asco22 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | Faculty @PC31 | Associate Director @PennPrecisMed | Tweets my own